Pharmacological Determinants of mRNA Vaccine Performance: RNA Chemistry, Lipid Nanoparticle Formulation, and Next-Generation Platforms

mRNA vaccines have moved from a largely theoretical platform to a clinically validated modality since the emergency authorizations of the first COVID-19 mRNA vaccines. Their efficacy is not simply a product of the encoded antigen. It emerges from a set of interconnected molecular decisions made at the level of RNA chemistry, sequence architecture, and formulation design. Nucleoside substitutions alter innate immune recognition and translational kinetics. Codon usage shapes ribosomal throughput and protein yield. The lipid nanoparticle (LNP) vehicle controls how, where, and for how long the mRNA payload is delivered. Treating these variables as interconnected pharmacological parameters, rather than as independent engineering choices, is important to advancing mRNA vaccine science.Despite the clinical success of first-generation mRNA vaccines, several mechanistic questions remain incompletely resolved and are directly relevant to improving future products. The structure-activity relationships linking specific nucleoside modifications, such as N1-methylpseudouridine, to the magnitude and duration of antigen expression have not been systematically mapped across delivery contexts and tissue environments. Codon optimization strategies that maximize translational efficiency while avoiding unintended innate immune activation require further experimental validation beyond computational prediction. On the formulation side, the ionizable lipid component of LNPs is the principal determinant of endosomal escape, yet the relationship between lipid pKa, membrane fusogenicity, and organ-specific tropism is not fully characterized. Self-amplifying RNA (saRNA) platforms, which encode their own replicase machinery and may enable lower-dose regimens with extended antigen expression, introduce additional pharmacokinetic complexity that warrants rigorous pharmacological investigation. This Research Topic aims to consolidate current mechanistic knowledge, identify unresolved gaps, and provide a focused, peer-reviewed reference for rational mRNA vaccine design.Contributions are invited on the following themes:• Nucleoside chemistry and its effect on mRNA stability, immunogenicity, and translational output• Codon optimization methodologies and their experimental validation• Ionizable lipid design and the physicochemical determinants of LNP potency• Biodistribution, tissue tropism, and pharmacokinetic modelling of LNP-mRNA systems• Comparative pharmacological characterization of self-amplifying or circular RNA constructs• Innate immune sensing at the interface of RNA chemistry and lipid vehicleIn vitro, preclinical, and clinical findings are all within scope. This Research Topic does not cover antigen/immunogen design in isolation from delivery pharmacology, non-mRNA vaccine platforms, or agricultural/veterinary applications, which fall outside the scope of this collection. Accepted article types include, among others, original research articles, systematic reviews, narrative reviews, mini-reviews, and perspectives. Authors should frame their findings within the broader context of vaccine pharmacology and their translational relevance to infectious disease. Topic editors: KAUSHIKA PATEL, Anupam Mukherjee, Paresh Patel, Pragya Jatoo Source: https://www.frontiersin.org/research-topics/84020/pharmacological-determinants-of-mrna-vaccine-performance-rna-chemistry-lipid-nanoparticle-formulation-and-next-generation-platforms